My Companies
Notification
Account
Log Out
Login
Management guided FY27 consolidated revenue of at least ₹1,550 crore and PAT of at least ₹178 crore (11.4% margin), with FY28 commercialisation of sickle-cell testing and medical devices. It proposed an energy demerger, affordable CAR-T centres, UK/Swiss subsidiaries, two oncology hospitals and 50 dialysis centres by March 2027.
Lords Mark Industries To Consider ₹100 Crore Convertible Promoter Loan
Lords Mark Industries Achieves 25% MPS After Second Promoter Stake Sale
Lords Mark Industries Promoter Sells 2.43 Percent Stake Via Open Market
Lords Mark Industries Enters ARKALL Collaboration Targeting US$100 Million Export Revenue
Lord's Mark Receives India's First Biomescan SaMD Manufacturing Licence